What question did this study set out to answer?

To delineate the cellular mechanisms of extracellular free haem toxicity during haemolysis and assess the protective, therapeutic, and diagnostic roles of haemopexin.

February 1, 2017ISBT Science Series

Mechanisms of haem toxicity in haemolysis and protection by the haem‐binding protein, haemopexin

View Full Paper

Ask AI

Bookmark

Authors

ASArnold L. SmithSeattle Children's Hospital RMRussell J. McCullohUniversity of Nebraska at Omaha

Discussion

Member takes

Implication

Narrative review uncovers protective mechanisms of haemopexin against haem toxicity in haemolytic diseases, highlighting its utility as a biomarker and therapeutic agent.

Key Points

To delineate the cellular mechanisms of extracellular free haem toxicity during haemolysis and assess the protective, therapeutic, and diagnostic roles of haemopexin.
Reviewed cellular pathways governing haem-mediated cytotoxicity, inflammation, and metal trafficking through endocytic compartments.
Evaluated proof-of-principle preclinical trials testing haemopexin protein replacement and hepatic gene therapy in murine models of sickle cell disease and sepsis.
Synthesized clinical and longitudinal patient data comparing haemopexin to haptoglobin as a biomarker for intravascular haem load.
Endocytosis of haem–haemopexin complexes co-regulates safe intracellular trafficking of three redox-active metals without inducing cytotoxic reactions.
Haemopexin uniquely stimulates signalling cascades and transcription factors that trigger antioxidant enzyme synthesis, preserving redox balance compared to uncontrolled free haem exposure.
Haemopexin serves as a superior clinical plasma biomarker to haptoglobin for monitoring chronic haem load because it directly binds haem and is not an acute-phase reactant.

Cite This Study

Smith et al. (2017) studied this question.

synapsesocial.com/papers/6a7ddbb8cecc27a187a14ee7 https://doi.org/10.1111/voxs.12340

View Full Paper

Ask AI

Bookmark

Implication

Narrative review uncovers protective mechanisms of haemopexin against haem toxicity in haemolytic diseases, highlighting its utility as a biomarker and therapeutic agent.

Mechanisms of haem toxicity in haemolysis and protection by the haem‐binding protein, haemopexin

Discussion

Member takes

Implication

Key Points

Cite This Study

Mechanisms of haem toxicity in haemolysis and protection by the haem‐binding protein, haemopexin

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider